Previous 10 | Next 10 |
Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN * Clinical Practice Guidelines in Oncology (NCCN Guidel...
2024-02-22 21:24:07 ET Veracyte, Inc. (VCYT) Q4 2023 Earnings Conference Call February 22, 2024 04:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Office...
2024-02-22 16:32:42 ET More on Veracyte Veracyte Q4 revenue to grow by 18%-20% Y/Y Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracyte Financial information for Veracyte Read the full article on Seeking Alpha ...
Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023....
2024-02-21 17:20:51 ET More on Veracyte Veracyte Q4 revenue to grow by 18%-20% Y/Y Seeking Alpha’s Quant Rating on Veracyte Historical earnings data for Veracyte Financial information for Veracyte Read the full article on Seeking Alpha ...
Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will present at the Raymond James 45 th Annual Institutional Investors Conference on Monday, March 4, 2024, at 9:50 a.m. Eastern Time. A live...
2024-02-13 13:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general ...
Extends Veracyte’s novel diagnostics platform with whole-genome minimal residual disease capabilities Expands company’s presence across the cancer care continuum Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has complet...
2024-02-02 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Grew total revenue to $96.8 million, an increase of 17% Grew testing revenue by 25% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong s...
Large number of abstracts also showcases power of the Veracyte Diagnostics Platform Veracyte, Inc . (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show ...
2024-04-25 09:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...